Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Apr 15, 2024 1:14pm
66 Views
Post# 35989701

RE:RE:RE:RE:RE:RE:Quentin30 is a pathological prevaricator.

RE:RE:RE:RE:RE:RE:Quentin30 is a pathological prevaricator.
Just for clarification ... 

Lyophilization has been used in the pharmaceutical industry for decades. It involves freezing a product and removing the water while it is frozen. The resulting product is a stable lyophilized powder that can be stored for long periods at room temperature.

The lyophilization process involves three main steps: freezing, primary drying, and secondary drying. The product is frozen at a low temperature, typically between -40°C and -80°C. This process turns the product into a solid, which allows it to dry without losing its properties.


Easy Transport and Storage: Lyophilized products are easy to transport and store. They can be transported at room temperature, which reduces the need for refrigeration or other special storage conditions, making them more convenient and accessible to patients.

https://www.broughton-group.com/blog/lyophilized-products-the-benefits-of-freeze-drying-to-increase-product-shelf-life-and-stability
<< Previous
Bullboard Posts
Next >>